Blogs | | Chimeric antigen receptor T-cell therapy targeting CD19 is highly effective for inducing remission among patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Despite that, 50% of patients relapse after CAR-T therapy, and curative options for patients who relapse after CD19 CAR-T are limited, with no standard approach to cure.
Supercharging the body’s immune system to attack tumor cells holds tremendous promise. Your support is instrumental to making this frontier of cancer research possible.
Fred Hutch molecular biologist and oncologist Dr. Andrew Hsieh was elected to the American Society for Clinical Investigation for his work demonstrating how changes in protein synthesis can drive cancer.
Fred Hutch molecular biologist and oncologist Dr. Andrew Hsieh was elected to the American Society for Clinical Investigation for his work demonstrating how changes in protein synthesis can drive cancer.
A team lead by Fred Hutch physician-scientist Dr. Marie Bleakley has shown it can dramatically reduce chronic GVHD, a common debilitating side effect of stem cell transplantation in leukemia patients, using magnets to remove “naïve T cells” from the mixture of blood cells from a donor that are to be transplanted into the patient.